Jeffrey Chou

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Igor Puzanov, Mohammed Milhem, David R. Minor et al. · Journal of Clinical Oncology · 2016 · 542 citations · Full text

Activation of m-Calpain (Calpain II) by Epidermal Growth Factor Is Limited by Protein Kinase A Phosphorylation of m-Calpain

Hidenori Shiraha, Angela Glading, Jeffrey Chou et al. · Molecular and Cellular Biology · 2002 · 174 citations · Full text

Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide

Christopher G. Kanakry, David G. Coffey, Andrea Towlerton et al. · JCI Insight · 2016 · 142 citations · Full text

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, Reinhard Dummer, Antoni Ribas et al. · Journal of Clinical Oncology · 2016 · 110 citations

Immunology, Immune Regulation, Immunoediting +22

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

Igor Puzanov, Mohammed Milhem, Robert Hans Ingemar Andtbacka et al. · Journal of Clinical Oncology · 2014 · 82 citations

Ipi Tx, Immunology, Immunoediting +22